149 related articles for article (PubMed ID: 38880492)
21. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of persistence and remission with guselkumab
Zhdanava M; Fitzgerald T; Pilon D; Teneralli RE; Shah A; Diaz L; Lefebvre P; Feldman SR
J Dermatolog Treat; 2024 Dec; 35(1):2349658. PubMed ID: 38747375
[No Abstract] [Full Text] [Related]
23. Bibliometric analysis of RNA vaccines for cancer.
Yang X; Kang J; Xing Z; Sun Y; Liu Z; Li N; Niu J
Hum Vaccin Immunother; 2023 Aug; 19(2):2231333. PubMed ID: 37464256
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
[TBL] [Abstract][Full Text] [Related]
25. A bibliometrics study on the status quo and hot topics of pathogenesis of psoriasis based on Web of Science.
Yang Y; Zheng X; Lv H; Tang B; Bi Y; Luo Q; Yao D; Chen H; Lu C
Skin Res Technol; 2024 Jan; 30(1):e13538. PubMed ID: 38174774
[TBL] [Abstract][Full Text] [Related]
26. Global Research Trends on Infertility and Psychology From the Past Two Decades: A Bibliometric and Visualized Study.
Zhu H; Shi L; Wang R; Cui L; Wang J; Tang M; Qian H; Wei M; Wang L; Zhou H; Xu W
Front Endocrinol (Lausanne); 2022; 13():889845. PubMed ID: 35903282
[TBL] [Abstract][Full Text] [Related]
27. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
[TBL] [Abstract][Full Text] [Related]
28. Unveiling global research trends and hotspots on mitochondria in NAFLD from 2000 to 2023: A bibliometric analysis.
Hu J; Chen Z; Zhou Y; Li Y; Liu J; Mi Y; Wang L; Jiang F; Li P
Immun Inflamm Dis; 2024 Mar; 12(3):e1226. PubMed ID: 38533910
[TBL] [Abstract][Full Text] [Related]
29. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
30. A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022.
Luo Q; Tang Z; Wu P; Chen Z; Fang Z; Luo F
Front Endocrinol (Lausanne); 2023; 14():1218968. PubMed ID: 38093957
[TBL] [Abstract][Full Text] [Related]
31. Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
[TBL] [Abstract][Full Text] [Related]
32. Knowledge Mapping of Exosomes in Autoimmune Diseases: A Bibliometric Analysis (2002-2021).
Wu F; Gao J; Kang J; Wang X; Niu Q; Liu J; Zhang L
Front Immunol; 2022; 13():939433. PubMed ID: 35935932
[TBL] [Abstract][Full Text] [Related]
33. Immune-related adverse events: A bibliometric analysis.
Jiang ST; Liu YG; Zhang L; Sang XT; Xu YY; Lu X
Front Immunol; 2022; 13():1096806. PubMed ID: 36591239
[TBL] [Abstract][Full Text] [Related]
34. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
[TBL] [Abstract][Full Text] [Related]
35. Treatment of erythrodermic psoriasis with biologics: A systematic review.
Carrasquillo OY; Pabón-Cartagena G; Falto-Aizpurua LA; Santiago-Vázquez M; Cancel-Artau KJ; Arias-Berrios G; Martín-García RF
J Am Acad Dermatol; 2020 Jul; 83(1):151-158. PubMed ID: 32247872
[TBL] [Abstract][Full Text] [Related]
36. Global diabetic kidney disease research from 2000 to 2017: A bibliometric analysis.
Zou LX; Sun L
Medicine (Baltimore); 2019 Feb; 98(6):e14394. PubMed ID: 30732183
[TBL] [Abstract][Full Text] [Related]
37. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
38. Management of Residual Psoriasis in Patients on Biologic Treatment.
Haidari W; Pona A; Feldman SR
J Drugs Dermatol; 2020 Feb; 19(2):188-194. PubMed ID: 32129969
[TBL] [Abstract][Full Text] [Related]
39. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
40. Global Trends and Hotspots on Microglia Associated with Pain from 2002 to 2022: A Bibliometric Analysis.
Dong G; Li H; Gao H; Chen Y; Yang H
J Pain Res; 2023; 16():2817-2834. PubMed ID: 37600079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
